An accurate assessment of glomerular filtration rate (GFR) is a fundamental aspect of cancer care and research. Recent studies have demonstrated that, in patients with solid tumors, GFR estimation based on serum creatinine combined with serum cystatin C presented minimal bias compared to measured GFR, may reduce race disparity when applied to race free GFR estimating equations, and improve the prediction of carboplatin clearance.
BenzingTSalantD. Insights into glomerular filtration and albuminuria. N EnglJ Med2021; 384: 1437–1446.
2.
RosnerMHBoltonWK. Renal function testing. Am J Kidney Dis2006; 47: 174–183.
3.
SprangersBAbudayyehALatchaS, et al. How to determine kidney function in cancer patients. Eur J Cancer2020; 132: 141–149.
4.
CasalMANolinTDBeumerJH. Estimation of kidney function in oncology - implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol2019; 14: 587–595.
5.
SprangersBPerazellaMALichtmanSM, et al. Improving cancer care for patients with chronic kidney disease: the need for changes in clinical trials. Kid Int Rep2022; 7(9): 1939–1950.
6.
LevinAStevensPBilousRW. Kidney disease: improving global outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl2013; 3: 1–150.
7.
LeveyASGramsMDMInkerLA. Uses of GFR and albuminuria level in acute and chronic kidney disease. N Engl J Med2022; 386: 2120–2128.
8.
LeveyASInkerLA. Assessment of glomerular filtration rate in health and disease : a state of the art review. Clin Pharmacol Ther2017; 102: 405–419.
9.
MussapMMario PlebaniM. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci2004; 41: 467–550.
10.
LeveyASCoreshJTighiouartH, et al. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol2020; 16: 51–64.
11.
VillasenorABallard-BarbashRBaumgartnerK, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv2012; 6: 398–406.
12.
SteneGBHelbostadJLAmundsenT, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol2015; 54: 340–348.
13.
GioulbasanisIMartinLBaracosVE, et al. Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?Ann Oncol2015; 26: 217–221.
14.
Ramos ChavesMBoléo-ToméCMonteiro-GrilloI, et al. The diversity of nutritional status in cancer: new insights. Oncologist2010; 15(5): 523–530.
15.
LetoGCrescimannoMFlandinaC. On the role of cystatin C in cancer progression. Life Sci2018; 202: 152–160.
16.
KosJWerleBLahT, et al. Cystein proteinases and their inhibitors in extracellular fluids: marker for diagnosis and prognosis in cancer. Int J Biol Markers2000; 15: 84–89.
17.
StrojanPSveticBSmidL, et al. Serum cystatin C in patients with head and neck carcinoma. Clin Chim Acta2004; 344: 155–161.
18.
YanYZhouKWangL, et al. Expression of cystatin C and its effect on EC9706 cells in oesophageal carcinoma. Int J Clin Exp Pathol2015; 8: 10102–10111.
19.
KosJKrašovecMCimermanN, et al. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Cancer Res2000; 6: 505–511.
20.
ZhangWWangSWangQ, et al. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. Oncol Rep2014; 31: 1334–1342.
21.
YanYZhouKWangL, et al. Clinical significance of serum cathepsin B and cystatin C levels and their ratio in the prognosis of patients with esophageal cancer. Onco Targets Ther2017; 10: 1947–1954.
22.
CoxJL. Cystatins and cancer. Front Biosci Landmark Ed2009; 14: 463–474.
23.
KepplerD. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett2006; 235: 159–176.
24.
MagisterSKosJ. Cystatins in immune system. J Cancer2013; 4: 45–56.
25.
StabucBVrhovecLStabuc-SilihM, et al. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem2000; 46: 193–197.
26.
NakaiKKikuchiMFujimotoK, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol2008; 12: 132–139.
27.
BodnarLWcisloGBSmoterM, et al. Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res2010; 33: 360–367.
28.
JonesMDenieffeSGriffinC, et al. Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. Pract Lab Med2017; 8: 95–104.
29.
RasouliAHMoghadamMMTabatabaiefarM, et al. Comparing Cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer. Acta Med Iran2012; 50: 43–46.
30.
HeLLiJZhanJ, et al. The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis. Cancer Chemother Pharmacol2019; 83: 561–571.
31.
BolkeESchierenGGrippS, et al. Cystatin C: a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients. Strahlenther Onkol2011; 187: 191–201.
32.
ChancharoenthanaWWattanatornSVadcharavivadS, et al. Agreement and precision analyses of various estimated glomerular filtration rate formulae in cancer patients. Sci Rep2019; 18: 19356.
33.
Costa e SilvaVTGilLAInkerLA, et al. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int2022; 101: 607–614.
34.
InkerLAEneanyaNDCoreshJ, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021; 385: 1737–1749.
35.
DelgadoCBawejaMCrewsDC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. J Am Soc Nephrol. 2021; 32: 2994–3015.
36.
Costa e SilvaVTGilLAJrInkerLA, et al. A prospective cross-sectional study on the performance of the 2021 CKD-EPI equations without race in a multi-racial population of adults with solid tumors in Brazil. In American Society of Clinical Oncology Meeting June 2022, Chicago. (Abstract number 310, American Society of Clinical Oncology, Virginia).
37.
ThomasFSeronie-VivienSGladiefL, et al. Cystatin C as a new covariate to predict renal elimination of drugs application to carboplatin. Clin Pharmacokinet2005; 44: 1305–1316.
38.
TsangSAkbariAFrechetteD, et al. Accurate determination of glomerular filtration rate in adults for carboplatin dosing: moving beyond Cockcroft and Gault. J Oncol Pharm Practice2021; 27: 368–375.
39.
SchmittAGladieffLLansiauxA, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res2009; 15: 3633–3639.
40.
White-KoningMPaludettoMNLe LouedecF, et al. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance. Cancer Chemother Pharmacol2020; 85: 585–592.
